High-dose epirubicin, preceded by dexrazoxane, given in combination with paclitaxel plus filgrastim provides and effective mobilizing regimen to support three courses of high-dose dense chemotherapy in patients with high-risk stage II-IIIA breast cancer

U. De Giorgi, G. Rosti, A. Zaniboni, M. Ballardini, M. R. Minzi, M. Baioni, E. Ferrari, L. Zornetta, M. Marangolo

Research output: Contribution to journalArticle

Abstract

We verified the possibility of collecting large amounts of peripheral blood stem cells (PBSCs) to support three courses of adjuvant high-dose dense chemotherapy (HDDC) with high-dose epirubicin, preceded by dexrazoxane, and high-dose paclitaxel, in patients with high-risk breast cancer (≥ 9 positive nodes). The mobilizing regimen consisted of high-dose epirubicin 150 mg/m2, preceded by dexrazoxane 1000 mg/m2 (day 1), given in combination with paclitaxel 175 mg/m2 (day 2), plus filgrastim. Of the 25 patients enrolled, one went off study due to a severe hypersensitivity reaction to paclitaxel, another did not undergo leukapheresis due to fever persistent after hematological recovery, while in 23 patients an adequate number of PBSCs was collected by a single leukapheresis. The median number of CD34+, CD34+/CD33-, and CD34+/CD38- cells collected per patient was 17 × 106/kg, 13.4 × 106/kg, and 1.5 × 106/ kg, respectively. Neutropenia was the only grade 4 toxicity and lasted a median of 3 days. High-dose epirubicin, preceded by dexrazoxane for the first time used in mobilizing regimen, and paclitaxel plus filgrastim are effective in releasing large amounts of PBSCs, which can then be safely employed to support multiple courses of HDDC.

Original languageEnglish
Pages (from-to)251-255
Number of pages5
JournalBone Marrow Transplantation
Volume32
Issue number3
DOIs
Publication statusPublished - Aug 2003

Keywords

  • Breast cancer
  • Dexrazoxane
  • Epirubicin
  • Filgrastim
  • Paclitaxel
  • Stem cell mobilization

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Fingerprint Dive into the research topics of 'High-dose epirubicin, preceded by dexrazoxane, given in combination with paclitaxel plus filgrastim provides and effective mobilizing regimen to support three courses of high-dose dense chemotherapy in patients with high-risk stage II-IIIA breast cancer'. Together they form a unique fingerprint.

  • Cite this